Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Trial Profile

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPARZ
  • Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
    • 05 Jun 2018 Results (n=209) of pooled subgroup analysis (NCT00720941 and NCT01147822) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results of an integrated molecular profiling in 409 patients from this trial, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top